



**THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN**

**ARPIDA WITHDRAWS EUROPEAN MARKETING APPLICATION FOR INTRAVENOUS ICLAPRIM IN cSSTI AS A RESULT OF NEGATIVE OUTCOME OF CHMP HEARING**

- **No impact on intended merger with Evolva**
- **EGM planned 26 November 2009**

**Reinach, Switzerland, 20 October 2009.** Arpida Ltd (SIX: ARPN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has reached a negative opinion on the market authorisation application (MAA) for intravenous iclaprim in complicated Skin and Soft Tissue Infections (cSSTI) in the European Union. Subsequently, Arpida decided to withdraw the MAA.

“We are obviously disappointed”, Dr Jürgen Raths, Arpida CEO commented, “but after the FDA decision of January this year, the CHMP recommendation does not come as a complete surprise. It confirms that a resumption of the iclaprim development programme would require large investments that are beyond our reach. As a consequence, we will no longer pursue the programme and continue the search for a partner for the compound. The proposed merger with Evolva is not impacted as iclaprim was never part of the transaction. At the planned Extraordinary General Meeting (EGM) we will ask our shareholders to support a new and promising perspective by merging Arpida and Evolva.”

In the coming weeks, all registered Arpida shareholders will receive an invitation to the EGM to be held on 26 November in Reinach (BL), Switzerland. The agenda will include several items related to the proposed merger with Evolva.

- ends -

**Contacts:**

Dr Jürgen Raths, President and CEO

Tel: + 41 61 417 96 60

Harry Welten, MBA, CFO and Senior Vice President

Tel: + 41 61 417 96 65

Paul Verbraeken, Head of Corporate Communications

Tel: + 41 61 417 96 83

THIS PRESS RELEASE CONSTITUTES NEITHER AN OFFER TO SELL NOR A SOLICITATION TO BUY ANY SECURITIES AND IT DOES NOT CONSTITUTE AN OFFERING PROSPECTUS WITHIN THE MEANING OF ARTICLE 652a OF THE SWISS CODE OF OBLIGATIONS OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE LISTING RULES OF SIX SWISS EXCHANGE AG.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND MUST NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OR INVITATION TO PURCHASE ANY SECURITIES IN THE

UNITED STATES. THE SECURITIES OF ARPIDA LTD. HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS.

INVESTORS ARE FURTHERMORE ADVISED TO CONSULT THEIR BANK OR FINANCIAL ADVISOR.

This publication contains specific forward-looking statements, *e.g.*, statements including terms like "believe", "assume", "expect" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.